358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancerA. Bardia,L.M. Spring,D. Juric,A. Partridge,J. Ligibel,I. Kuter,J. Peppercorn,H. Parsons,P. Ryan, D. Chawla, V. Attaya, D.M. Fitzgerald, E. Viscosi, B. Lormill, M. Shellock,B. Moy, S.M. Tolaney,L.W. EllisenAnnals of Oncology（2020）引用 3|浏览39暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
